Quantification of the structure and composition of the vessel wall and assessment of lipid-rich necrotic core plaque (CPT 0710T-0713T) BOSTON – December 17, 2021 – Elucid, a Boston-based medical technology company harnessing scientific imaging and artificial...
Press Releases
Elucid Eyes Big Opportunity to Save Lives with Software Amidst Major Guideline Changes
ACC/AHA Endorse Cardiovascular Computed Tomography Angiography (CCTA) in New Chest Pain Guidelines BOSTON--(BUSINESS WIRE)--Elucid, a medical technology company developing AI software to enable cardiovascular disease detection, expects newly issued guidelines will be...
Elucid Secures $8 Million in Series A Funding Led by MedTex Ventures and Global Health Impact Fund
Elucid, today announced $8 Million in Series A financing led by MedTex Ventures and Global Health Impact Fund.